Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Oramed Pharmaceuticals Inc(ORMP)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ORMP
11/13/2026: ORMP (2-star) is currently NOT-A-BUY. Pass it for now.
Oramed Pharmaceuticals is a clinical-stage biotechnology company focused on its proprietary oral drug delivery platform, POD. The company's value proposition centers on developing non-invasive oral alternatives to traditional injectable drugs for diabetes treatment. While the firm has a dedicated focus on a significant market, it faces substantial risks, including a lack of commercial revenue, a history of challenging clinical outcomes, and intense competition from established pharmaceutical leaders. The stock is best suited for speculative investors who understand the high risk of biotechnology R&D. Key developments to monitor include future clinical trial data and any potential licensing agreements for their delivery technology.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | The company is highly speculative and lacks the consistent growth track record preferred by typical growth investors. |
| Momentum investor | Mixed fit | This is a conditional fit based on positive news flow and price upturn signals, but it lacks steady momentum. |
| Value investor | Weak fit | Lack of earnings and commercial products makes traditional value assessment inapplicable. |
| Dividend investor | Weak fit | Oramed does not pay dividends and reinvests all capital into high-risk R&D. |
| Low-risk investor | Weak fit | High clinical, regulatory, and financial risk profiles make this unsuitable for low-risk investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is highly sensitive to clinical trial data and regulatory news. |
| Valuation risk | High | Valuation is difficult due to the absence of commercial revenue and uncertain clinical success. |
| Competition risk (Diabetes treatment market) | High | Established players have massive resources that create high barriers to entry. |
| Business quality | Low | The company lacks a proven commercial business model or steady income streams. |
| Dividend income | Low / none | There is no history or expectation of dividend payments. |
| Execution risk | High | Success depends entirely on the high-risk, multi-year clinical trial process. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 154.33M USD | Price to earnings Ratio 0.9 | 1Y Target Price 7 |
Price to earnings Ratio 0.9 | 1Y Target Price 7 | ||
Volume (30-day avg) 121.3K shares | Beta 1.28 | 52 Weeks Range 2.10 - 5.47 | Updated Date 11/13/2026 |
52 Weeks Range 2.10 - 5.47 | Updated Date 11/13/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 4.13 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 27.23% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/13/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development | Clinical trial advancement of ORMD-0801. | The company generates no recurring revenue and relies on capital raises to fund research. |
Earnings Date
Report Date 2026-11-12 | When After Market | Estimate 0.43 | Actual -0.16 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -3.26% | Return on Equity (TTM) 53.52% |
Valuation
Trailing PE 0.9 | Forward PE - | Enterprise Value 117.97M | Price to Sales(TTM) - |
Enterprise Value 117.97M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 24.02 | Enterprise Value to EBITDA 1.55 | Shares Outstanding 41.60M | Shares Floating 31.18M |
Shares Outstanding 41.60M | Shares Floating 31.18M | ||
Percent Insiders 21.27 | Percent Institutions 46.02 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.